18
December
2024
Vela
Technologies plc
("Vela"
or
"the Company")
Interim
results for
the
six
months ended
30
September
2024
Vela Technologies plc (AIM: VELA),
an AIM-quoted investing company focused on early stage and pre-IPO
disruptive technology investments, today announces its unaudited
interim results for the six months ended 30 September
2024.
Overview
The last six months have continued
to be challenging for the small-cap marketplace in the UK. As
reported in its latest quarterly report, announced on 28 November
2024, the Board has concluded that it cannot continue to wait for
the long-expected upturn in markets. Accordingly, the Board
continues proactively to look to realise certain of the existing
investment portfolio, where possible without crystallising material
losses, with the intention of recycling the proceeds into new
investment opportunities. During the period Vela sold all its
holding in MTI Wireless Edge Limited and part holdings in EnSilica
plc and Skillcast Group plc, realising a profit on all
sales.
During the period the Company
reports a significant fair value loss on the investment portfolio,
predominately arising from the fall in the share price of Conduit
Pharmaceuticals Inc. ("Conduit"). As
at 30 September 2024 Conduit's share price
had fallen to $0.12, giving a fair value of only £89,000, as
reported in the latest quarterly update. The share price has since sunk to
$0.10 as at the date of this announcement. On 16 August 2024
Conduit announced that it had become aware that one of its
directors had previously entered into certain collateral pledge
agreements that resulted in the disposition of a substantial number
of shares in Conduit and that it had appointed an independent
committee of the Conduit board to establish the facts. Another
independent committee of the Conduit board was formed to
investigate and review the trading patterns of certain of Conduit
shareholders and to determine if any action should be taken. It
seems that the irregularities were instrumental in the collapse of
the share price. The Board of Vela is very disappointed with the
performance of the investment in Conduit and shares the
frustrations of shareholders.
Vela made one new investment during
the period, issuing shares valued at £300,000 to Hamak Gold Limited
in exchange for a convertible loan note. Under the terms of the investment in the convertible loan note
in Hamak, Hamak undertook to redeem £75,000 of the convertible loan
note at a minimum rate of £10,000 per month from 31 July 2024
onwards. At the date of this report Vela is yet to receive any such
payments and continues to be in discussions with the Hamak
board in order to reach a mutually
beneficial longer-term solution.
Since the period-end Vela has made a
further investment in Igraine Plc, an existing investee company, by
way of a convertible loan note of no less than £250,000 in tranches
of £50,000, the first of which had been advanced by the date of
this announcement. Since the period end Vela has also sold partial
holdings in both Finseta plc and EnSilica plc, generating gross
proceeds of £21,263 and £71,535 respectively.
Turning to the financials, the
balance sheet has decreased, principally because of the revaluation
of Conduit, with total assets amounting to £3.804 million as at 30
September 2024 (30 September 2023: £7.542 million; 31 March 2024:
£6.291 million). Cash and cash equivalents as at 30 September 2024
were £103,000 (31 March 2024: £54,000; 30 September 2023: £31,000).
The Board remains committed to keeping running costs to a
minimum.
As at 30 September 2024, the
investment portfolio comprises a total of 14 active investee
companies and two legacy investments which have been valued at £nil
for a number of years. 13 of the active investee companies are held
as investments on the balance sheet having a fair value of £2.652
million as at 30 September 2024 (31 March 2024: £5.487 million; 30
September 2023: £2.789 million). The remaining investment is
a convertible loan note held at a cost of £300,000 (30 September
2023: £nil; 31 March 2024 £nil). Investments are
held at fair value through profit and loss using a three-level
hierarchy for estimating fair value, as detailed in the audited
financial statements for the year ended 31 March 2024, and, in line
with this, investments have been revalued to reflect the fair value
at 30 September 2024.
The Board looks forward to the
remainder of the financial year ending 31 March 2025 with caution
but ever mindful of potential new and follow-on investments in line
with its investing policy. The Board will continue to update
shareholders, in line with regulatory guidelines, via its quarterly
investment updates and regulatory announcements. The directors would like to thank shareholders for their
continued support.
Brent Fitzpatrick
Chairman
18 December 2024
Unaudited Statement of Comprehensive Income
for
the six months ended 30 September 2024
|
|
(Unaudited)
|
(Unaudited)
|
(Audited)
|
|
|
6 months
ended
|
6 months
ended
|
Year
Ended
|
|
|
30
September
|
30
September
|
31
March
|
|
|
2024
|
2023
|
2024
|
|
Notes
|
£'000
|
£'000
|
£'000
|
|
|
|
|
|
Revenue
|
|
-
|
-
|
-
|
|
|
|
|
|
Fair value
movements
|
|
|
|
|
- on derivatives
|
|
-
|
(55)
|
-
|
- on financial asset
|
|
-
|
1,250
|
-
|
- on investments
|
|
(2,603)
|
(518)
|
(357)
|
Net (deficit) / surplus arising from
fair value movements
|
|
(2,603)
|
677
|
(357)
|
Administrative expenses
|
|
(127)
|
(181)
|
(443)
|
Operating (loss) / profit
|
|
(2,742)
|
496
|
(800)
|
Finance income
|
|
6
|
6
|
23
|
(Loss) / profit
before tax
|
|
(2,736)
|
502
|
(777)
|
Income tax
|
|
-
|
-
|
-
|
(Loss) / profit / after
tax
|
|
(2,736)
|
502
|
(777)
|
|
|
|
|
|
Other comprehensive income for the
year
|
|
-
|
-
|
-
|
|
|
|
|
|
Total comprehensive (loss) /
profit
|
|
(2,736)
|
502
|
(777)
|
Attributable to:
|
|
|
|
|
Equity holders of the company
|
|
(2,736)
|
502
|
(777)
|
(Loss) / profit per share
|
|
|
|
|
Basic and
diluted (loss) / profit per share (pence)
|
4
|
(0.016)
|
0.0031
|
(0.0050)
|
Unaudited
Balance Sheet
as
at 30 September 2024
|
|
(Unaudited)
30
September
|
(Unaudited)
30
September
|
(Audited)
31
March
|
|
|
2024
|
2023
|
2024
|
|
Notes
|
£'000
|
£'000
|
£'000
|
Non-current assets
|
|
|
|
|
Investments
|
5
|
2,652
|
2,789
|
5,487
|
Trade and other
receivables
|
6
|
718
|
4,704
|
718
|
Total
non-current assets
|
|
3,370
|
7,493
|
6,205
|
|
|
|
|
|
Current assets
|
|
|
|
|
Trade and other
receivables
|
|
300
|
-
|
-
|
Derivative financial instruments
|
7
|
32
|
18
|
32
|
Cash and cash equivalents
|
|
103
|
31
|
54
|
Total current
assets
|
|
435
|
49
|
86
|
Total assets
|
|
3,805
|
7,542
|
6,291
|
|
|
|
|
|
Equity and liabilities
|
|
|
|
|
Equity
|
|
|
|
|
Called-up share capital
|
8
|
3,563
|
3,291
|
3,320
|
Share premium reserve
|
|
7,672
|
7,594
|
7,615
|
Share-based payment reserve
|
|
6
|
46
|
6
|
Retained earnings
|
|
(7,439)
|
(3,424)
|
(4,703)
|
Total equity
|
|
3,802
|
7,507
|
6,238
|
Current liabilities
|
|
|
|
|
Trade and other payables
|
|
3
|
35
|
53
|
Total current liabilities
|
|
3
|
35
|
53
|
Total equity and
liabilities
|
|
3,805
|
7,542
|
6,291
|
Unaudited
Cashflow Statement
for
the six months ended 30 September 2024
|
(Unaudited)
6 months
ended
|
(Unaudited)
6 months
ended
|
(Audited)
year
ended
|
|
30
September
|
30
September
|
31
March
|
|
2024
|
2023
|
2024
|
|
£'000
|
£'000
|
£'000
|
Operating activities
|
|
|
|
Loss / profit before tax
|
(2,736)
|
502
|
(777)
|
Share based payment
|
-
|
-
|
-
|
Fair value movements on investments
|
2,603
|
(732)
|
357
|
Fair value movements on derivative
instruments
|
-
|
55
|
-
|
Finance income
|
-
|
(6)
|
(23)
|
(Decrease) / increase in payables
|
(50)
|
2
|
15
|
Total cash flow from operating
activities
|
(183)
|
(179)
|
(428)
|
Investing activities
|
|
|
|
Interest received
|
-
|
-
|
14
|
Proceeds from sale of investments
|
232
|
136
|
344
|
Payment for put option
|
-
|
(400)
|
-
|
Purchase of investments
|
-
|
(250)
|
(650)
|
Total cash flow from investing
activities
|
232
|
(514)
|
(292)
|
Financing activities
|
|
|
|
Proceeds from the issue of ordinary
shares
|
-
|
-
|
50
|
Total cash flow from financing
activities
|
-
|
-
|
50
|
|
|
|
|
Net increase / (decrease) in cash and cash
equivalents
|
49
|
(693)
|
(670)
|
Cash and cash equivalents at start of
year/period
|
54
|
724
|
724
|
Cash and cash equivalents at the end
of the year/period
|
103
|
31
|
54
|
Cash and cash equivalents
comprise:
|
|
|
|
Cash at bank
|
103
|
31
|
54
|
Cash and cash equivalents at end of
year / period
|
103
|
31
|
54
|
Unaudited
Statement of Changes in Equity
for
the six months ended 30 September 2024
|
Share capital
|
Share Premium
|
Share Option Reserve
|
Retained Earnings
|
Total Equity
|
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
Balance at 1 April 2024
|
3,320
|
7,615
|
6
|
(4,703)
|
6,238
|
Share
issue
|
243
|
57
|
-
|
-
|
300
|
Loss and total
comprehensive income for the period
|
-
|
-
|
-
|
(2,736)
|
(2,736)
|
Balance at 30 September
2024
|
3,563
|
7,672
|
6
|
(7,439)
|
3,802
|
|
|
|
|
|
|
Balance at 1 April 2023
|
3,291
|
7,594
|
46
|
(3,926)
|
7,005
|
Profit and total comprehensive income for the
period
|
-
|
-
|
-
|
502
|
502
|
Balance at 30 September
2023
|
3,291
|
7,594
|
46
|
(3,424)
|
7,507
|
|
|
|
|
|
|
Balance at 1 April 2023
|
3,291
|
7,594
|
46
|
(3,926)
|
7,005
|
Share-based payment
|
-
|
-
|
(40)
|
-
|
(40)
|
Share issue
|
29
|
21
|
-
|
-
|
50
|
Loss and total comprehensive income for the
period
|
-
|
-
|
-
|
(777)
|
(777)
|
Balance at 31 March 2024
|
3,320
|
7,615
|
6
|
(4,703)
|
6,238
|
Notes to the
Interim Accounts
for
the six months ended 30 September 2024
1. General
information
Vela Technologies plc is a company incorporated
in the United Kingdom.
These unaudited condensed interim financial
statements for the six months ended 30 September 2024 have been
prepared in accordance with International Financial Reporting
Standards (IFRS) and IAS 34 "Interim Financial Reporting" as
adopted by the European Union and do not constitute statutory
accounts as defined in Section 434 of the Companies Act 2006.
This condensed set of financial statements has been prepared
applying the accounting policies that were applied in the
preparation of the Company's published financial statements for the
year ended 31 March 2024 and are presented in pounds
sterling.
The comparative figures for the financial year
ended 31 March 2024 have been extracted from the Company's
statutory accounts which have been delivered to the Registrar of
Companies and reported on by the Company's Auditors. Their
report was unqualified and contained no statement under section 298
(2) or (3) of the Companies Act 2006.
2.
Changes in accounting policy
The assessment of new standards,
amendments and interpretations issued but not effective are not
anticipated to have a material impact on the interim financial
statements.
3. Going concern
The Directors have considered the
Company's activities, together with the factors likely to affect
its future development and performance, the financial position of
the Company, and its cash flows and liquidity position, taking
account of the current market conditions. This review has
demonstrated that the Company shall continue to operate within its
own resources.
The Directors believe that the
Company is well placed to manage its business risks successfully
and that the Company has adequate resources to continue in
operational existence for the foreseeable future.
Accordingly, they consider it appropriate to adopt the going
concern basis in preparing these condensed financial
statements.
4.
(Loss) / profit per share
(Loss) / profit per share has been
calculated on a loss of £2,736,000 (six months to 30 September
2023: £502,000 profit; year to 31 March 2024: £777,000 loss) and
the weighted number of average shares in issue for the period of
17,556,553,841 (30 September 2023: 16,252,335,184; 31 March 2024:
16,546,452,831).
|
6 months
ended
30
September
2024
|
6 months
ended
30
September 2023
|
Year
ended
31
March
2024
|
(Loss) / profit (£'000)
|
(2,736)
|
502
|
(777)
|
(Loss) / earnings per share (pence)
|
(0.016)
|
0.0031
|
(0.005)
|
5.
Investments
|
Other
Investments
£'000s
|
Fair value at 1 April 2024
|
5,487
|
Additions during the period
|
-
|
Disposals during the period
|
(232)
|
Current period fair value movement charged to
profit or loss
|
(2,603)
|
Fair value at
30 September 2024
|
2,652
|
Investment in Hamak Gold Limited and
issuance of share capital
In July 2024 the Company entered
into an unsecured convertible loan note instrument with Hamak Gold
Limited ("Hamak"), the Liberia-based gold
exploration and development company. Vela issued
2,424,242,424 new ordinary shares of 0.01 pence each to Hamak at a
deemed issue price of 0.012375 pence per share in consideration of
the issue to Vela by Hamak of £300,000 of unsecured convertible
loan notes of £1. The deemed issue price represented a premium of
7.61 per cent. to Vela's closing mid-market price of 0.0115p on 16
July 2024.
Part disposal of shares in EnSilica plc
During the period the Company
disposed of an aggregate of 160,000 shares at an average price of 59p per share, generating gross
proceeds of £94,029 for the Company. Following the disposals Vela
remained interested in 616,707 ordinary shares as at 30 September
2024.
Part disposal of shares in Skillcast Group
plc
During the period the Company
disposed of a total of 100,000 shares at an
average price of 44p per share, generating gross proceeds of
£44,685 for the Company. Following the disposals Vela remained
interested in 575,676 ordinary shares as at 30 September
2024.
Disposal of holding in MTI Wireless Edge Ltd
In September 2024 the Company
disposed of its entire holding of 200,000 shares
at a price of 46p per share, generating gross
proceeds of £92,000 for the Company.
6. Trade and other receivables -
non-current
|
30
September
|
30
September
|
31
March
|
|
2024
|
2023
|
2024
|
|
£'000
|
£'000
|
£'000
|
Loan due from Bixx Tech Limited
|
718
|
704
|
718
|
Other financial asset
|
-
|
4,000
|
-
|
|
718
|
4,704
|
718
|
Loan due from
Bixx Tech Limited
The loan represents the consideration
receivable for the disposal of certain investment assets in August
2020. The total consideration receivable is £855,000, which
is receivable after seven years. The consideration has been
discounted at a market interest rate of 4.5%.
Under the terms of the loan
agreement, the Company has provided an undertaking to distribute a
sum equal to any repayment of the loan to the holders of the
Special Deferred Shares. Details of these arrangements are set out
in the audited financial statements for the year ended 31 March
2024. This distribution will be by way of a dividend declared on
the Special Deferred Shares ("the Special Dividend"). In the event
that insufficient distributable reserves exist at the end of the
seven-year loan term, the repayment of the loan will be deferred
for a further year. This deferral will continue until such a time
as the Company has sufficient distributable reserves to be able to
pay the Special Dividend.
Other financial asset -
Investment in St George Street Capital
On 20 October 2020, the Company
entered into a contract with St George Street Capital ("SGSC") for
an 8% economic interest in the potential future commercialisation
of SGSC's asset to treat individuals with diabetes who are
suffering with COVID-19 ("the Asset"). The consideration payable
under the terms of the contract was £2.35m which was settled by
cash of £1.25m and the issue of 1,100,000,000 locked-in
consideration shares at a price of 0.1 pence per share. The
directors considered that this represented the fair value of the
contract at the date of investment. The contract gave the
Company a right to future economic benefits and was classified as a
financial asset measured at fair value through profit and loss. The
contract did not include a defined exit date and so was classified
as non-current at previous reporting dates, as the Company did not
have an unconditional right to require settlement of the contract
within 12 months.
In April 2023, the Company announced
that it had entered into a put option agreement to give the Company
the right, but not the obligation, to sell its economic interest in
the commercialisation of the Covid-19 application of AZD1656 in
return for shares in Conduit Pharmaceuticals Limited ("Conduit").
The Option was granted by Conduit and its prospective parent
company, Murphy Canyon Acquisition Corp, a Company listed on
NASDAQ.
On 1 December 2023, Vela exercised
the put option to sell its economic interest in return for shares
in Conduit. Under the terms of the option agreement Vela
received 1,015,760 new shares of authorised common stock of par
value $0.001. In accordance with Vela's accounting policy, these
shares have been revalued using the market price at the balance
sheet date and is now included at fair value with other listed
investments.
7. Derivative financial
instruments
|
30
September
|
30
September
|
31
March
|
|
2024
|
2023
|
2024
|
|
£'000
|
£'000
|
£'000
|
Warrants
|
32
|
18
|
32
|
|
32
|
18
|
32
|
|
|
|
|
The Company holds warrants providing
it with the right to acquire additional shares in certain of its
investee companies at a fixed price in the future, should the
directors decide to exercise them. The warrants have been
recognised as an asset at fair value, which has been calculated
using an appropriate option pricing model.
8. Share capital
Allotted, called up and fully paid
capital
|
30
September
2024
|
30
September
2023
|
31
March
2024
|
18,970,695,255 Ordinary Shares of 0.01 pence
each
|
1,897
|
1,625
|
1,654
|
1,748,943,717 Deferred Shares of 0.08
pence each
|
1,399
|
1,399
|
1,399
|
2,665,610,370 Special Deferred Shares
of 0.01 pence each
|
267
|
267
|
267
|
|
3,563
|
3,291
|
3,320
|
On 22 July 2024, 2,424,242,242
Ordinary 0.01 Shares were issued at a deemed issue price of
0.012375 pence per share in exchange for a convertible loan note in
Hamak Gold Limited valued at £300,000.
The number of shares in issue at 30
September 2024 were 18,970,695,255 (30 September 2023 and 31 March
2024: 16,546,452,831).
9. Financial
instruments
The Company is required to report
the category of fair value measurements used in determining the
value of its investments, to be disclosed by the source of its
inputs, using a three-level hierarchy. There have been no transfers
between Levels in the fair value hierarchy.
Quoted market prices in active
markets - "Level 1"
Inputs to Level 1 fair values are
quoted prices in active markets for identical assets. An
active market is one in which transactions occur with sufficient
frequency and volume to provide pricing information on an ongoing
basis. The Company has eleven (30 September 2023: twelve; 31
March 2024: twelve) investments classified in this category. The
aggregate historic cost of these investments is £5,691,316 (30
September 2023: £3,393,803; 31 March 2024: £5,831,316) and the fair
value as at 30 September 2024 was £1,823,795 (30 September 2023: £1,961,310; 31 March 2024:
£4,658,581)
Valued using models with significant
observable market parameters - "Level 2"
Inputs to Level 2 fair values are
inputs other than quoted prices included within Level 1 that are
observable for the asset, either directly or indirectly. The
Company has two (30 September 2023: two; 31 March 2024: two)
unquoted investments classified in this category. The historic cost
of these investments is £450,000 (30 September 2023: £450,000; 31
March 2023: £450,000) and the fair value as at 30 September 2023
was £828,186 (30 September 2023; £828,186; 31 March 2024:
£828,186).
Valued using models with significant
unobservable market parameters - "Level 3"
The Company has two (30 September
2023: two; 31 March 2024: two) legacy investments that are held at
an aggregate carrying value of £nil at 30 September 2024 (30
September 2023: £nil; 31 March 2024: £nil) because they appear to
be inactive, based on the information held by Vela. As at 30
September 2024 the historical cost of this investment amounted to
£300,000 (30 September 2023: £300,000; 31 March 2024:
£300,000).
The Company also holds a convertible
loan note at a fair value of £300,000 (30 September 2023: £nil; 31
March 2024: £nil). The historic cost of the asset is £300,000
(30 September 2023: £nil; 31 March 2024: £nil).
10. Related party transactions
During the period the Company entered into the
following related party transactions. All transactions were made on
an arm's length basis:
Ocean Park Developments
Limited
Brent Fitzpatrick, non-executive
chairman, is also a director of
Ocean Park Developments Limited. During the
period the Company paid £24,000 (six months
ended 30 September 2023: £24,000; year ended 31 March 2024:
£62,000) in respect of his director's fees to Ocean Park
Developments Limited. The balance due to Ocean Park
Developments Limited at the period end was £nil (30 September 2023
£nil; 31 March 2024: £nil).
11.
Principal risks and uncertainties
Principal risks and uncertainties
are set out in the annual financial statements within the
directors' report and also in note 14 to those financial statements
and are reviewed on an on-going basis.
The Board provides leadership within
a framework of appropriate and effective controls. The Board has
set up, operates and monitors the corporate governance values of
the Company, and has overall responsibility for setting the
Company's strategic aims, defining the business objective, managing
the financial and operational resources of the Company and
reviewing the performance of the officers and management of the
Company's business both prior to and following an
acquisition.
There have been no significant
changes in the first six months of the financial year to the
principal risks and uncertainties as set out in the 31 March 2024
Annual Report and Accounts.
12.
Board approval
These interim results were approved
by the Board of Vela Technologies plc on 18 December
2024.